{
    "organizations": [],
    "uuid": "dbed060f4b8ba451279ce5e28669f4ec816ee853",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-intervacc-progress-in-development/brief-intervacc-progress-in-development-of-new-vaccine-against-staphylococcus-aureus-infections-idUSFWN1P503A",
    "ord_in_thread": 0,
    "title": "BRIEF-Intervacc: Progress In Development Of New Vaccine Against Staphylococcus Aureus Infections",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 10 (Reuters) - INTERVACC AB:\n* SIGNIFICANT PROGRESS HAS BEEN MADE IN THE DEVELOPMENT OF A NEW VACCINE AGAINST STAPHYLOCOCCUS AUREUS INFECTIONS\n* ‍COSTS RELATED TO MASTITIS ARE ESTIMATED ANNUALLY ABOUT 200 MSEK ONLY IN SWEDEN AND IN US ABOUT 4500 MSEK​\n* SAYS ‍NEED FOR A VACCINE TO COMPLEMENT OTHER PREVENTIVE MEASURES IS VERY LARGE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-01-10T15:41:00.000+02:00",
    "crawled": "2018-01-11T12:43:22.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "intervacc",
        "ab",
        "significant",
        "progress",
        "made",
        "development",
        "new",
        "vaccine",
        "staphylococcus",
        "aureus",
        "infection",
        "related",
        "mastitis",
        "estimated",
        "annually",
        "msek",
        "sweden",
        "u",
        "say",
        "vaccine",
        "complement",
        "preventive",
        "measure",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}